The application of artificial intelligence in lung cancer: a narrative review

Huixian Zhang1,2,3#, Die Meng1,2#, Siqi Cai1,2#, Haoyue Guo1,2, Peixin Chen1,2, Zixuan Zheng1,2, Jun Zhu1,2, Wencheng Zhao1, Hao Wang1,2, Sha Zhao1, Jia Yu1, Yayi He1

1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China; 2Tongji University, Shanghai, China; 3Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Contributions: (I) Conception and design: Y He, H Zhang, D Meng, S Cai; (II) Administrative support: None; (III) Provision of study materials or patients: Y He, H Zhang, W Zhao; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*These authors contributed equally to this work.

Correspondence to: Yayi He. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No. 507 Zhengmin Road, Shanghai 200433, China. Email: 2250601@qq.com.

Objective: This review was conducted to systematically summarize the progress made by artificial intelligence technology in early screening based medical imaging, pathological diagnosis, genomics inspection, prognostic evaluation, and individual treatment of lung cancer.

Background: Lung cancer has a high mortality rate in China, which is closely related to the fact that most lung cancer patients are not diagnosed until the malignancy is advanced. Challenges remain in the early detection, accurate diagnosis, monitoring and individual treatment of lung cancers. Artificial intelligence has developed to process large amounts of data, from clinical presentations to physiological images, which is essential for solving the complex issues with clinical medicine. Increasing evidence has suggested that artificial intelligence technology provides novel, promising strategies for the diagnosis and treatment of lung cancer.

Methods: A review of literature was conducted in PubMed, EMBASE and Cochrane to identify the latest research on artificial intelligence and lung cancer, and ultimately to generate a narrative review.

Conclusions: Artificial intelligence plays an important role in the imaging inspection, histopathology examination and genomics inspection of lung cancer. In addition, artificial intelligence has the ability to detect a small number of biomarkers, which is conducive to lung cancer monitoring. Moreover, the intelligent treatment of lung cancer has gradually become the trend of future development, whether in internal medicine or surgical treatment. It is believed that artificial intelligence could improve the early diagnosis of lung cancer and assist doctors in treating lung cancer patients individually.

Keywords: Lung cancer; artificial intelligence; early diagnosis; individual treatment

doi: 10.21037/tcr-20-3398

View this article at: http://dx.doi.org/10.21037/tcr-20-3398

Introduction

The leading cause of cancer-related deaths across the world is lung cancer (1-4). Most lung cancer patients are subject to late diagnosis and the lack of efficient treatment (5). More attention needs to be paid to rapid, sensitive and accurate detection techniques. At present, doctors mainly rely on the clinical features of patients and imaging characters to diagnose lung cancer. However, these methods are ineffective in finding lesions timely
Artificial intelligence (AI) is referred to as the ability of a digital computer or a robot controlled by a digital computer to carry out some assignments that meet people's needs (6). A large number of studies have demonstrated that AI is not only valid in detection, dynamical monitor, but also in quantitative treatment during the process of health protection, thus revealing a major capacity for cancer care (7,8). In this review, we will discuss the application of AI in lung cancer and the challenges in clinical application (Figure 1). We present the following article in accordance with the Narrative Review reporting checklist (available at http://dx.doi.org/10.21037/tcr-20-3398).

**AI and detection**

*Imaging inspection*

Clinically, when patients feel uncomfortable or have suspected lesions, their whole body or a certain part will be scanned by means of digital radiography (DR), computed tomography (CT), positron emission computed tomography (PETCT), or magnetic resonance imaging (MRI) (9,10). These imaging techniques as mentioned above play an important role in cancer diagnosis. The main practical problem facing doctors is that their access to information and the integration of digital images of visible anomalies cannot be consistent and accurate (9,11,12).

In an attempt to obtain information instantly with no omission, AI developed its logical algorithm to detect pictures fast. Computer-aided detection (CAD) systems are applied to determine the target site in clinical pictures (13). AI-based detection tools can mark the lesion sites, reduce observational oversights, and make it convenient for readers. For example, CAD systems are easy to distinguish between bronchioles, lung wall and parenchyma clearly while highlighting the lesions that are different than normal, which enables the physicians to ascertain changes without error (12). On the other hand, computer-aided diagnosis systems have paid attention to classifying benign and malignant nodules (14). Up to now,
new approaches have been designed to detect and diagnose the lung nodules sized less than 3 mm (15). AI aims to tailor specific solutions to a certain person based on the texture of tumor, character, staging and invasion area.

The imaging features of early lung cancer are pure ground-glass nodule (GGN), partially solid or solid nodule (16). The early detection and surgical resection of lung cancer, presented as GGN or partial solid nodules, can increase the 5-year survival rate to over 95% (17). Cancerous pulmonary nodules are difficult to distinguish from benign ones in the early stages. The most suitable solution to lung cancer screening is low-dose CT (LDCT) (18). However, for radiologists, the early detection of lung cancer nodules is very challenging.

The application of AI can overcome the shortage of radiologists and is conducive to the early diagnosis of lung cancer. In recent years, there has been remarkable progress made by the CAD system of pulmonary nodules using traditional machine learning (ML) approaches (19). Recent studies have shown that AI technology in pulmonary nodule imaging is superior to radiologists in detecting the GGN of more than 5 mm and screening the nodules of 0~3 mm (20). However, CAD systems cannot be used alone in clinical practice. Vasopressors (VS)-CAD system, also known as the ClearRead CT software, which was approved by the US Food and Drug Administration (FDA) in 2016, can improve the detectability of small pulmonary nodules by inhibiting the normal structures in the lung, mainly blood vessels (21).

With the development of AI, deep learning (DL) and convolutional neural networks (CNNs) have shown their massive potential in the detection of pulmonary nodules and are effective in segmenting and classifying pulmonary nodules (22). Hua et al. established a DL-based CT detection system for the pulmonary nodules with a sensitivity of 73% and specificity of 80%, which is superior to the traditional CAD system (23). Ardila and his colleagues developed a DL-based model to predict the risk of developing the lung cancer by analyzing the recent and previous CT volume of patients (24). Nevertheless, detecting pulmonary nodules by AI still needs to be verified in practice and it requires more cases for rectification (25).

Histopathology inspection

Traditionally, pathological examination has been identified as the most important criterion for the diagnosis of lung cancer, which is an effective approach to digging out changes compared with the surrounding tissue and to identifying the nature of the biopsy species (26-28). However, most patients who undergo biopsies are at an advanced stage and cannot be cured. In addition, what has been taken is just a part of tumor that can’t indicate lesions entirely (29). The vast majority of pathological methods are limited to discriminating equivocal histological features, especially in poorly differentiated tumors (9). Drawing upon multiple strands of research into AI, histological analysis can be conducted to develop exhaustive and intelligent diagnostic tactics for biopsy sample (29).

The studies on identifying sensitive and specific method to make diagnosis is widely established. A novel source of large data for personalized medicine was collected by using high-throughput whole-slide scanning technologies and through image computing. Compared with routine clinical images, AI gets integrated with data information prognostically and predicatively to make accurate histology slides analysis (30). Moreover, pathologists can speed up workflow by using the automatic machines that may offer large volume slides and conduct analysis excellently (9,31). Immunohistochemical (IHC) staining that works in mucin staining is an easily available technique that helps to standardize the assessment of the subtype of lung cancer (29,32). In the study of Koh et al., a reliable IHC panel was applied to diagnose the histological subtype of lung cancer thoroughly. They employed two AI approaches including a support vector machine (SVM) and a decision tree to ascertain ambiguous morphology from 30 small biopsy cases of lung cancer. In the absence of 3-marker IHC panel (i.e., TTF-1, Napsin A and p40), they achieved the highest accuracy of approximately 72% based on the decision tree model that performed two markers (p63 and CK5/6) (33). Although AI expedites workflow and provides precious images to help diagnose lung cancer, the application of AI in clinical settings is rare. The most important reason is that the technology algorithm has not been improved sufficiently to meet the needs of extended patients. In addition, the high price is also a barrier to the widespread application of AI.

Genomics inspection

With the release of the whole genome sequence and functional genomics data, individualized medical genetics assists with therapy decisions and helps practitioners to prescribe an appropriate therapy for a certain patient. The overexpression of a proto-oncogene or disruption caused by a tumor suppressor gene may lead to cell transformation and tumor formation (34-36). In recent researches, proto-
oncogenes and tumor-suppressor genes have been identified as markers for the diagnosis of cancer (30). For example, the mutations in the epidermal growth factor receptor (EGFR) gene or rearrangement of the anaplastic lymphoma kinase (ALK) receptor gene are conspicuous in lung cancer, and they are the molecular targets for custom therapeutic selection (37).

The gene conveys semblance of lung cancer by establishing microarrays and AI understands genomic pathways by optimizing algorithm (38,39). Cancer subtype, tumor growth and metastatic potential can be predicted using AI classifiers (40,41). With the growth of the next generation and other methods to reveal the sequences of gene appearance, clinicians will be able to rely on the genomic data to make individual treatment decisions (42). Watson for Genomics (WfG) is being developed to analyze the results of genetic sequencing for patients (43). A study was conducted to evaluate the effectiveness of WfG, in which the gene sequencing results of patients, including lung cancer patients with lung cancer, were first analyzed by hospital multidisciplinary experts and then reanalyzed by WfG (44). According to the results reported, for the 249 oncogenic alterations identified using both approaches, 84.6% of the targeted therapies proposed by experts were covered by WfG which also provided an additional 225 treatment options.

**AI and monitor**

Liquid biopsy, which is distinct from the traditional approaches retrieving biopsy arduously and huge invasively, is developed as a tool for screening. Liquid biopsy makes great contribution to determining the possible genomics alterations which will guide treatment options (6). In recent years, some studies have been conducted to reveal a variety of biomarkers, such as tumor-associated antigens (TAAs), circulating tumor DNA (ctDNA), tumor-associated autoantibodies (TAAbs), tumor educated platelets (TEP), and others (45).

Currently, the studies on liquid biopsy in cancer diagnosis are focused on the AI developed ML to detect a small number of biomarkers. ML is a part of AI and it is a great algorithm to find millions of microcirculatory genomics fragments that are more sensitive and earlier to be found compared with traditional methods (46). However, due to the limitation of tumor interstitial heterogeneity, there is still a long way to go for the application of liquid biopsy in clinical practice (11,47).

**AI and treatment**

With the development of AI, the intelligent diagnosis and treatment of lung cancer has gradually become the trend of future development. Clinical decision support system (CDSS) is a tool to assist clinicians in making clinical decisions through the comprehensive analysis of clinical knowledge (including clinical guidelines, evidence-based medicine, drug instructions, etc.) as well as the basic and clinical information on patients through AI (48). Watson for Oncology (WFO), as the best representative of CDSS, has been used in the diagnosis and treatment of some cancers, including lung cancer. A retrospective study was conducted to evaluate the consistency of WFO and multidisciplinary teams (MDT) in the treatment of lung cancer cases (49). The results suggested that the overall coincidence rate between MDT and WFO was 92.4% in lung cancer patients. The treatment recommendations for stage I and IV lung cancers are highly consistent. However, it is relatively low in stage II-III NSCLC and localized small cell lung cancer. In particular, the compliance rate for stage III NSCLC was only 80.8%.

Nevertheless, CDSS cannot completely replace doctors. Instead, it can play a supplementary role, especially for the patients with complex conditions. Moreover, due to the complexity of clinical medicine, doctor-patient communication and shared decision making may play a more important role in treatment.

**Surgery**

Video-assisted thoracic surgery (VATS) has been widely applied to treat lung cancer (50,51). A large number of previous studies have demonstrated that compared with thoracotomy, thoracoscopic lobectomy is characterized by less trauma, faster postoperative recovery and fewer complications (52). However, due to the limitations of thoracoscopy and surgical instruments, there will be some blind spots in the operation. In addition, the instrument arm is not as flexible as required to carry out more complex thoracoscopic surgery (53).

AI promises to revolutionize the way surgery is taught and practiced (54). Surgeons play a key role in integrating AI into clinical practice. The application of AI is beneficial for surgeons to analyze intraoperative progress in real time, improve the ability of intraoperative decision-making ability and finally improve the surgical outcomes (55). Robot surgery, which belongs to the physical branch of AI,
is a new direction of development for minimally invasive surgery (56). As a representative of robot surgery, the Da Vinci-robot-assisted thoracic surgery (RATS) has a precise system and convenient operation function, thus breaking the limits of hands and eyes while reducing pain and trauma for patients. The safety and feasibility of the Da Vinci surgical system in lobectomy have been demonstrated in several studies (57-59). A meta-analysis reveals that RATS and VATS are equally effective and safe in treating non-small-cell lung cancer, but RATS lasts longer. In addition, there were no statistically significant differences observed between RATS and VATS in terms of intraoperative conversion to thoracotomy rate, the incidence of postoperative complications, postoperative in-hospital mortality, intraoperative blood loss, postoperative drainage days and postoperative hospital stay (58). On the other hand, despite the above-mentioned advantages of RATS, there are some controversies surrounding this technology, such as the higher hospital costs and longer operation time, which may limit the development of RATS.

Radiotherapy

Chemoradiotherapy is the standard treatment for non-resectable advanced non-small cell lung cancer (NSCLC) (60,61). The combination of the AI and radiation contributes much in the development of radiology, which is conducive to realizing precision treatment (62,63). In a study, a clinical model of stereotactic body radiotherapy (SBRT) was designed for lung cancer patients using knowledge-based algorithms to plan treatment (64). In this study, 105 SBRT plans to treat lung cancer patients were involved, including 97 intensity modulated radiotherapy (IMRT), 6 volumetric arc radiotherapy (VMAT), and 2 three-dimensional conformal radiationtherapy (CRT). Knowledge-based model (KBM) training was carried out by combining the forementioned technologies, and multiple verification results showed that SBRT plans for lung cancer generated by KBM was comparable to clinical plans. Existing radiation techniques are designed to eliminate tumors, but they often cause damage to healthy tissue. The application of AI will solve the problem effectively and be able to adjust the volume of treatment. In addition, the optimal angle and radiation beam can be selected automatically without being influenced by the posture of patients (65). Furthermore, intelligent system has the ability to regulate irradiation time, dose rate and images. It is believed that physicians will make plans rapidly and precisely using AI (66,67).

Targeted therapy

Targeted therapy is a new approach to treat cancer with minimal damage to normal tissues by targeting molecules on tumor cells and developing effective blockers to intervene in the carcinogenesis process (68-70). Determining which location changed and what happened in the mutation region is an important step when we want to proceed. AI provides a large amount of data and enables an in-depth investigation, which supports us in finding various ways to prepare for useful option. In addition, intelligent machine establishes related model to find targeted gene or relational molecular pathway and make it visible.

With the assistance of AI, newly discovered therapeutic targets can be virtually screened in a very short time to find targeted old drugs or new compounds (71). AI-assisted reverse docking could be highly effective in reapplying old drugs or natural products to new indications (72). The characteristics of absorption, distribution, metabolism, excretion and toxicity (ADMET) can also be predicted by the DL model of AI, so as to improve the success rate of in vivo experiments (73).

Immunotherapy

The evaluation of immunotherapy for immune-responsive malignancies, particularly lung cancer, shows significant promise (74). Immune checkpoint inhibitors (ICIs), such as inhibitors of programmed death-1 (PD-1), cytotoxic correlative antigen-4 (CTLA-4), and programmed death-ligand 1 (PD-L1), exert prospective effects in advanced lung cancer (75-77).

However, some challenging problems arising from this domain are patient selection and immune response (78,79). Most of prior researches focused on predictive biomarkers about histological and genetic markers from biopsies (80). Charoenpong et al. made a major contribution to setting up a score scheme using AI that can be applied to predict the response of patients to ICIs (81). In addition, Coroller et al. used CT data to demonstrate the radiomic feature after treatment (82).

The Keynote-042 study revealed that the expression of PD-L1 was closely related to the curative effect, and that the higher the expression level of PD-L1, the more significant the benefit of immunotherapy in NSCLC patients (83). The detection method of PD-L1 is simple,
convenient, straightforward, and less demanding on dyeing technology. However, there are still many problems, for example, the imbalance of detection method, strong subjectivity in the doctor’s interpretation and the difficulty in giving quantitative data. AI technology has been successfully applied to the segmentation and recognition of tumor cells in tumor pathological images. Besides, it can also accurately quantify the results of IHC staining. Therefore, AI can detect the expression of PD-L1 in lung cancer tissues objectively and repeatably, which is conducive to predicting the efficacy of immunotherapy (84).

More effective biomarkers than PD-L1 are needed to predict efficacy. The toughest challenge for immunotherapy is that the process of treatment response is difficult to monitor because of dynamic changes. Once someone accepts immunotherapy, the following variation can hardly be ascertained accurately and completely. Although immunotherapy is hard to meet the final goals currently, precision treatment is made promising by the rapid development of AI (85).

**Future challenges**

The application of AI in understanding and treating lung cancer is advancing, but there still remain many obstacles to overcome. In healthcare settings, AI should follow unified planning and total target, as well as normalized and standard principle established by the authority that provides refined details to practice in real situation easily (62).

ML is a way to implement AI, which learns from examples rather than being programmed. Generally speaking, more examples are required for ML than human to master the same skill (56). Therefore, data acquisition is also of great importance. It is an easy way to obtain the medical records information of patients from electronic health records, which demonstrate all detailed information of the patient in hospital. Because of different recording requirements in disparate departments or districts, however, a large number of fragmented records present a challenge to the clinical application of AI (86). Moreover, language and culture barriers, patient privacy, sample volumes are all obstacles to obtaining available data (87,88).

**Conclusions**

The aspiration to improve the efficacy and efficiency of health care continues to drive diverse creations into practice, including AI. It has developed widespread and is essential for solving complex issues in multiple areas. Herein, we explained multiple applications of AI in the care of lung cancer patients. Currently, the researches on AI in oncology mainly focus on diagnosis, dynamic monitoring and personal treatment. By using intelligent machines to process vast amounts of data, from clinical presentations to physiological images, physicians can make decisions quickly and accurately. Moreover, computer-assisted diagnosis will help to detect early lesions, which is beneficial to the prognosis of patients. Due to the lack of standard databases, standardization principles formulated by authoritative institutions, and corresponding national policies and regulations, the application of AI in lung cancer has a broad prospect, despite a long way to go. To realize the goal of individual treatment, more sensitive and precise machines or algorithms are needed.

**Acknowledgments**

**Funding:** This study was supported in part by a grant of National Natural Science Foundation of China (81802255), Clinical research project of Shanghai Pulmonary Hospital (FKLY20010), Young Talents in Shanghai (2019 QNBJ), ‘Dream Tutor’ Outstanding Young Talents Program (fkyq1901), Clinical research project of Shanghai Pulmonary Hospital (FKLY20001), Respiratory medicine, a key clinical specialty construction project in Shanghai, Promotion and application of multidisciplinary collaboration system for pulmonary non infectious diseases, Clinical Research Project of Shanghai Pulmonary Hospital (fkcx1905), Key Discipline in 2019 (oncology), Project of Shanghai Municipal Science and Technology Commission (Project of Municipal Science and Technology Commission), Scientific research project of Shanghai Pulmonary Hospital (fkcx1903), Shanghai Municipal Commission of Health and Family Planning (2017YQ050), Innovation Training Project of SITP of Tongji University, and key projects of leading talent (19411950300), Youth project of hospital management research fund of Shanghai Hospital Association (Q1902037).

**Footnote**

**Reporting Checklist:** The authors have completed the Narrative Review reporting checklist. Available at http://dx.doi.org/10.21037/tcr-20-3398

**Conflicts of Interest:** All authors have completed the ICMJE
uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-3398). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that the questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


49. Kim MS, Park HY, Kho BG, et al. Artificial intelligence and lung cancer treatment decision: agreement with recommendation of multidisciplinary tumor board. Transl...


77. Prendergast CT, Sanin DE, Cook PC, et al. CD4+ T cell hyporesponsiveness after repeated exposure to Schistosoma...
mansoni larvae is dependent upon interleukin-10. Infect Immun 2015;83:1418-30.


